SPECIAL NOTICE
B -- Recovery - Exercise option under the National Academy of Sciences Task Order No. HHSH234H7605 entitled "A Framework and Process for Reviewing Possible Theories, Biological Mechanisms, and Relevant Literature Regarding Adverse Events Associated w/ Vaccines
- Notice Date
- 9/1/2009
- Notice Type
- Special Notice
- NAICS
- 541611
— Administrative Management and General Management Consulting Services
- Contracting Office
- Department of Health and Human Services, Health Resources and Services Administration, Division of Procurement Management, 5600 Fisher Ln., Room 13A-19, Rockville, Maryland, 20857, United States
- ZIP Code
- 20857
- Solicitation Number
- HRS15553
- Archive Date
- 9/14/2009
- Point of Contact
- Dottie L Watson, Phone: 301-443-2752
- E-Mail Address
-
dwatson@hrsa.gov
(dwatson@hrsa.gov)
- Small Business Set-Aside
- N/A
- Description
- The purpose of this announcement is to fulfill the disclosure requirement under the American Recovery and Reinvestment Act. It is provided for informational purposes only. The Health Resources and Services Administration (HRSA) intends to exercise an option under an existing task order (HHSH234H7605) with the National Academy of Science, Institute of Medicine using recovery act money. The task order is to develop a framework and process for reviewing possible theories, biologic mechanisms, and relevant literature regarding adverse events associated with vaccines. Specifically, NAS/IOM shall convene a committee to plan and hold a public workshop to discuss a framework for assessing hypotheses regarding adverse events associated with four vaccines - varicella, influenza, hepatitis B, and human papilloma virus. The Committee will also issue a report evaluating the scientific and medical evidence bearing on the causal relation between these vaccines and specific adverse events. If further funding becomes available, the committee will be asked to conduct a number of additional optional items which will increase the number of vaccines being reviewed. The option will add the review of four additional vaccines (constituting 8 antigens) - tetanus-containing vaccines, meningococcal vaccine, hepatitis A vaccine, and measles-mumps-rubella vaccine. The Committee will thus issue a report evaluating the scientific and medical evidence bearing on the causal relation between 8 vaccines (12 antigens) in total and specific adverse events. This award will be made utilizing American Recovery and Reinvestment Act (ARRA) funding to support HRSA's Bureau of Clinician Recruitment and Services ARRA efforts. This option would not have been exercised without the supplement provided from ARRA funding. The optional services will be delivered over a one year period. This announcement is for informational purposes. It is not a solicitation. The contact person for this requirement is Dottie Watson (301)443-2752 or dwatson@hrsa.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/2352ce3baf6656bc4f2691823c1b8b7b)
- Record
- SN01935786-W 20090903/090902004513-2352ce3baf6656bc4f2691823c1b8b7b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |